Table 5.
Active pancreas irreversible electroporation clinical trials (source: ClinicalTrials.gov)
|
Title
|
Location
|
Hyperlink
|
Patients
|
Estimated completion
|
| An open-label, multicenter, prospective study of IRE (Nano Knife) combined with radiotherapy and chemotherapy in patients with LAPC | Shanghai, China | https://clinicaltrials.gov/ct2/show/NCT04310553 | 40 | December, 2020 |
| Ablation of unresectable LAPC with IRE system | Teaneck, New Jersey, United States | https://clinicaltrials.gov/ct2/show/NCT03614910 | 30 | May, 2023 |
| Chemotherapy followed by irreversible electroporation in patients with unresectable LAPC | Aalborg, Denmark | https://clinicaltrials.gov/ct2/show/NCT04093141 | 30 | May, 2024 |
| Chemotherapy and IRE in the treatment of advanced pancreatic adenocarcinoma | Louisville, Kentucky, United States | https://clinicaltrials.gov/ct2/show/NCT03484299 | 20 | December, 2023 |
| PANFIRE-3 trial: Assessing safety and efficacy of IRE + Nivolumab + CpG for metastatic pancreatic cancer | Amsterdam, North-Holland, Netherlands | https://clinicaltrials.gov/ct2/show/NCT04612530 | 18 | October, 2022 |
| Outcomes of ablation of unresectable pancreatic cancer using the nanoknife IRE system | Baltimore, Maryland, United States | https://clinicaltrials.gov/ct2/show/NCT02041936 | 12 | December, 2021 |
| Immunotherapy and IRE in the treatment of advanced pancreatic adenocarcinoma | Louisville, Kentucky, United States | https://clinicaltrials.gov/ct2/show/NCT03080974 | 10 | April, 2022 |
| A study of the use of IRE in pancreatic ductal cancer | Toronto, Ontario, Canada | https://clinicaltrials.gov/ct2/show/NCT03257150 | 47 | September, 2021 |
| Safety and efficacy of IRE for LAPC | Seoul, Korea, Republic of | https://clinicaltrials.gov/ct2/show/NCT02898649 | 100 | August, 2019 |
| IRE (Nano Knife) for the treatment of pancreatic adenocarcinoma | Poitiers, France | https://clinicaltrials.gov/ct2/show/NCT03105921 | 20 | June, 2020 |
| IRE for inoperable hepatic and pancreatic malignancy | Hong Kong | https://clinicaltrials.gov/ct2/show/NCT02822716 | 35 | December, 2021 |
| Phase II/III of randomized controlled clinical research on IRE synchronous chemotherapy for LAPC | Guangzhou, Guangdong, China | https://clinicaltrials.gov/ct2/show/NCT03673137 | 120 | November, 2021 |
| Anti-tumor immunity induced by IRE of unresectable pancreatic cancer | Guangzhou, Guangdong, China | https://clinicaltrials.gov/ct2/show/NCT02343835 | 20 | January, 2025 |
| A pivotal study of safety and effectiveness of Nano Knife IRE for stage 3 pancreatic cancer | USA, Multicentre | https://clinicaltrials.gov/ct2/show/NCT03899636 | 528 | December, 2023 |
| Immunologic signatures following surgery for pancreatic cancer | Durham, North Carolina, United States | https://clinicaltrials.gov/ct2/show/NCT03001518 | 30 | April, 2027 |
IRE: Irreversible electroporation; LAPC: Locally advanced pancreatic cancer.